PLUR
Pluri, Inc.
NASDAQ · Healthcare · Biotechnology · IL
$0.85
−8.58%Year over year
Reported trailing growth
- Revenue
- -24.0%
- EBITDA
- -8.8%
- EBIT
- -12.5%
- EPS
- +34.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +52.4%
- EBITDA
- -10.7%
- EBIT
- -12.5%
- Net income
- -5.5%
- EPS
- +31.5%
- Free cash flow
- -2.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026